Overview

S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene

Status:
Recruiting

Trial end date:
2026-05-01

Target enrollment:

Participant gender:

Summary

This is a first-in-human Phase 1, multicenter, open-label dose escalation study of S095035 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A [MAT2A] inhibitor.

Phase:

Phase 1

Details

Lead Sponsor:

Servier Bio-Innovation LLC

Collaborator:

Institut de Recherches Internationales Servier